fenoldopam (Corlopam)
Jump to navigation
Jump to search
Introduction
Tradename: Corlopam (fenoldopam mesylate)
Indications
- emergency treatment of severe hypertension
- may benefit a subgroup of patients with acute tubular necrosis (ATN)[3]
- risk reduction for acute renal failure in critically ill patients[4]
- no benefit for acute kidney injury* after cardiac surgery[5]
* serum creatinine increase > 50% above baseline
Contraindications
- does NOT prevent contrast nephropathy
Adverse effects
- drug adverse effects of adrenergic receptor agonists
- drug adverse effects of dopaminergic receptor agonists
- drug adverse effects of sympathomimetic(s)
- drug adverse effects of antihypertensive agents
Mechanism of action
- dopamine D1 receptor agonist
- may inhibit catecholamine uptake
- increases blood flow to renal cortex & outer medulla
More general terms
References
- ↑ Journal Watch 23(24):193, 2003 Stone GW et al Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 290:2284, 2003 PMID: https://www.ncbi.nlm.nih.gov/pubmed/14600187
- ↑ The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996 pg 211-212
- ↑ 3.0 3.1 Journal Watch 25(17):135, 2005 Tumlin JA, Finkel KW, Murray PT, Samuels J, Cotsonis G, Shaw AD. Fenoldopam mesylate in early acute tubular necrosis: a randomized, double-blind, placebo-controlled clinical trial. Am J Kidney Dis. 2005 Jul;46(1):26-34. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15983954
- ↑ 4.0 4.1 Landoni G et al, Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: A meta-analysis of randomized clinical trials. Am J Kidney Dis 2007, 49:56 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17185146
- ↑ 5.0 5.1 5.2 Bove T et al. Effect of fenoldopam on use of renal replacement therapy among patients with acute kidney injury after cardiac surgery: A randomized clinical trial. JAMA 2014 Sep 29; PMID: https://www.ncbi.nlm.nih.gov/pubmed/25265449